Results 151 to 160 of about 13,388,853 (301)

Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice. [PDF]

Exp Mol Med, 2023
Pham TK, Nguyen THT, Yi JM, Kim GS, Yun HR, Kim HK, Won JC.   +6 more
europepmc   +1 more source

Effect of Sotagliflozin on Kidney Function and Cardio‐Kidney‐Metabolic Parameters Across Baseline eGFR Subgroups in Patients With Type 2 Diabetes and Stage 4 CKD

Diabetes, Obesity and Metabolism, EarlyView.
Vikas S. Sridhar, Luxcia Kugathasan, Manon Girard, Michael J. Davies, David Z. I. Cherney   +4 more
wiley   +1 more source

Dietary counselling and exercise training for lipid management in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, EarlyView.
Abstract Objectives Dyslipidaemia is highly prevalent among people living with human immunodeficiency virus (HIV) and contributes to increased cardiovascular risk. Although lifestyle interventions are recommended, evidence specific to people living with HIV remains limited. Previous reviews have primarily focused on dietary interventions or low‐density
Maki Aomori, Hitomi Maeda
wiley   +1 more source

Immunohistochemical Localization of Alogliptin, a DPP-4 Inhibitor, in Tissues of Normal and Type 2 Diabetes Model Rat. [PDF]

Acta Histochem Cytochem, 2022
Yamamoto Y, Ura K, Matsukawa T, Saita T, Shin M.   +4 more
europepmc   +1 more source

Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease

, 2015
Charles Andy Schuetz,1 Siew Hwa Ong,2 Matthias Blüher3 1Evidera Inc., Bethesda, MD, USA; 2Novartis Pharma AG, Basel, Switzerland; 3Department of Medicine, University of Leipzig, Leipzig, Germany Introduction: Dipeptidyl peptidase-4 (DPP-4 ...
Ong SH, Blüher M, Schuetz CA
core  

Gaps in diabetes care among people living with HIV and hypertension in Botswana: A cross‐sectional analysis of the InterCARE study

HIV Medicine, EarlyView.
Abstract Objectives Data on diabetes screening and monitoring, within HIV care programmes in sub‐Saharan Africa, remain limited. This study describes the quality of diabetes screening and management among people living with HIV with comorbid hypertension receiving care at facilities participating in the InterCARE trial in Botswana. Methods We conducted
Onkabetse Julia Molefe‐Baikai, Tshepo B. Leeme, Moagedi K. Mawi, Kago Kebotsamang, Thato Moshomo, Edwin Mogaetsho, Tendani Gaolathe, Kesaobaka Molebatsi, Matlhogonolo Kelepile, Keonayang Kgotlaetsile, Pooja Gala, Duolao Wang, Shabbar Jaffar, Laura M. Bogart, Lisa R. Hirschhorn, Mosepele Mosepele   +15 more
wiley   +1 more source

DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once? [PDF]

Endocrinol Metab (Seoul), 2022
Bae JC.
europepmc   +1 more source

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.

, 2008
Inhibition of dipeptidyl peptidase-4 (DPP-4) as a novel therapy for type 2 diabetes is based on prevention of the inactivation process of bioactive peptides, the most important in the context of treatment of diabetes of which is glucagon-like peptide-1 ...
Bo Ahrén, Ahrén, Bo
core  

Cardiovascular preventive role of thiazolidinedione in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention

Journal of Diabetes Investigation, EarlyView.
Among patients with type 2 diabetes undergoing percutaneous coronary intervention, thiazolidinedione use was independently associated with a significantly reduced risk of a composite of myocardial infarction, stroke, and all‐cause death, notably without an increased risk of admission for heart failure. ABSTRACT Background Thiazolidinediones (TZD) are a
Jinkwon Kim, Jimin Jeon, Joonsang Yoo, Minyoul Baik, Seok‐Jae Heo, Ji Woong Roh   +5 more
wiley   +1 more source

KCNQ1 rs163184 Variant Modulates Susceptibility to Classic and DPP-4 Inhibitor-Associated Bullous Pemphigoid. [PDF]

Int J Dermatol
Agiannitopoulos K, Achilla C, Poupounaki E, Meltzanidou P, Patsatsi A, Lazaridou E, Tzatzagou G, Lambropoulos A, Chatzikyriakidou A.   +8 more
europepmc   +1 more source